Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells1

  title={Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells1},
  author={Mattias Carlsten and H{\aa}kan Norell and Yenan T. Bryceson and Isabel Poschke and Kjell Schedvins and H G Ljunggren and Rolf Kiessling and Karl-Johan Malmberg},
  journal={The Journal of Immunology},
  pages={4921 - 4930}
The activating NK cell receptor DNAX accessory molecule-1 (DNAM-1) contributes to tumor immune surveillance and plays a crucial role in NK cell-mediated recognition of several types of human tumors, including ovarian carcinoma. Here, we have analyzed the receptor repertoire and functional integrity of NK cells in peritoneal effusions from patients with ovarian carcinoma. Relative to autologous peripheral blood NK cells, tumor-associated NK cells expressed reduced levels of the DNAM-1, 2B4, and… 

Figures from this paper

DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases

A general role for DNAM-1-CD155 interactions in NK cell-mediated killing of tumors, even in the presence of tumor CD70 or CD80 expression is implied, and the optimal efficacy requirements of cytokines that directly activate NK cells are defined.

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Investigation of the role of the DNAM-1/TIGIT/CD96 axis in the anti-tumor response of NK cells toward OC shows for the first time that checkpoint molecules TigIT/DNAM- 1/ CD96 play an important role inNK cell responsiveness against OC, and provides rationale for incorporating TIGIT interference in NK cell-based immunotherapy in OC patients.

Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor

Despite the pivotal role of natural killer (NK) cells in defenses against tumors, their exploitation in cancer treatment is still limited due to their reduced ability to reaching tumor sites and the

Influence of tumor cells on natural killer cell phenotype and cytotoxicity

Investigation of changes of both receptor phenotype and cytotoxic activity of NK cells cocultured with K562 and HepG2 cells in dual-chamber Transwell® plates demonstrated a decrease of NK cell cytotoxicity against K562 cells.

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D

DNAM-1 or NKG2D over-expression elicited a dynamic increase in NK cell degranulation against all sarcoma explants and cancer cell lines tested, including those that failed to induce a notable response in WT NK-92 cells.

NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions

An overview of recent advances in the study of melanoma cells’ susceptibility to NK cell-mediated lysis and how multiple receptor-ligand interactions participate in melanoma cell elimination is provided.

Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.

expression of DNAM-1 and NKG2D was reduced in NK cells of colon cancer patients, and this reduction could directly suppress the activation of NK cells, ultimately leading to the inhibition of NK cytotoxicity.

DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma

DNAM-1-based CARs may have the potential to treat PVR and nectin-2 expressing hematological and solid tumors.

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy

It can be speculated that in cancer patients the TIGIT/PVRIG pathways are upregulated and represent novel targets for checkpoint blockade immunotherapy.



DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

It is shown that human leukocyte antigen class I(low) tumor cells isolated directly from patients with advanced ovarian carcinoma trigger degranulation by resting allogeneic NK cells and identify ovarian carcinomas as a potential target for adoptive NK cell-based immunotherapy.

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.

It is shown that expression of the NK cell receptor DNAM-1 is reduced on CD56(dim) NK cells from myeloma patients with active disease compared with patients in remission and healthy controls, suggesting that this receptor might play a role in NK-myeloma interactions.

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Evidence is provided that CD94/NKG2A receptors play an important role in regulating T cell activity against tumors and shows that IFN-gamma modulation of target cells may shift the balance of triggering and inhibitory signals to T cells, turning off their cytolytic activity.

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors

DNAM-1 serves to extend the range of target cells that can activate CD8 T cell and NK cells and, hence, may be essential for immunosurveillance against tumors and/or viruses that evade recognition by other activating or accessory molecules.

Accelerated tumor growth in mice deficient in DNAM-1 receptor

Results indicate that DNAM-1 plays an important role in immune surveillance of tumor development and in response to the chemical carcinogens MCA and 7,12-dimethylbenz[a]anthracene (DMBA), respectively.

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.

Treatment with chNKG2D-expressing T cells is a potential immunotherapy for ovarian cancer, and it is shown that T cells from ovarian cancer patients that express chNKg2D secreted proinflammatory cytokines when cultured with autologous tumor cells.

Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)

The ovarian tumour marker MUC16 binds selectively to 30–40% of CD16+ CD56dim NK cells in EOC patients indicating that phenotypic alterations in these cells are mediated by tumour‐derived soluble factors.

NKp44, a Novel Triggering Surface Molecule Specifically Expressed by Activated Natural Killer Cells, Is Involved in Non–Major Histocompatibility Complex–restricted Tumor Cell Lysis

It is shown that p46 and NKp44 are coupled to the intracytoplasmic transduction machinery via the association with CD3ζ or KARAP/DAP12, respectively; these associated molecules are tyrosine phosphorylated upon NK cell stimulation.

CD107a as a functional marker for the identification of natural killer cell activity.

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.

This study suggests that in most instances the inability of NK cells to kill autologous leukemic blasts is consequent to low NCR surface expression, however, in few cases this failure appears to involve a mechanism of tumor escape based on down-regulation of ligands relevant for NCR-mediated target cell recognition.